Alprostadil (Caverject/MUSE) Cost in Minnesota 2026

What Does Alprostadil Actually Cost in Minnesota Right Now?

Brand-name alprostadil carries a manufacturer list price of roughly $600 per month in Minnesota in 2026, whether you are filling Caverject (intracavernosal injection) or MUSE (medicated urethral system for erection, a suppository). That figure holds across most Minnesota retail chains including Walgreens, CVS, and independent pharmacies without insurance. Cash prices vary slightly by dose and quantity, so a six-pack of Caverject 20 mcg vials may land closer to $350 to $400, while a 30-unit MUSE starter kit sits near $600 to $650 at most Twin Cities-area pharmacies.

Generic alprostadil injection (the sterile powder form) entered the U.S. market after Pfizer's exclusivity window and typically costs 20 to 40 percent less than brand Caverject. Even so, a monthly supply of generic intracavernosal alprostadil at 10 to 20 mcg per dose remains above $300 cash-pay in most Minnesota zip codes.

Alprostadil is a synthetic prostaglandin E1 analogue that relaxes trabecular smooth muscle and dilates cavernosal arteries, producing an erection independent of sexual stimulation and the nitric oxide pathway. Linet and Ogrinc demonstrated its clinical efficacy in a landmark 1996 NEJM double-blind trial, where 94 percent of injection attempts produced erections firm enough for intercourse versus 10.9 percent with placebo. That trial enrolled 683 men and established intracavernosal alprostadil as a first-line option for organic erectile dysfunction (ED).

The FDA approved Caverject in 1995 and MUSE in 1996, and both formulations remain on the FDA's list of approved drug products. Prescriptions require a licensed provider; alprostadil is not available over the counter in Minnesota or any other U.S. state.

How Minnesota Medicaid (Medical Assistance) Handles Alprostadil Coverage

Minnesota Medical Assistance (MA), the state's Medicaid program, covers alprostadil for refractory erectile dysfunction. Coverage requires prior authorization. The Minnesota Department of Human Services Preferred Drug List places alprostadil in a covered-with-PA tier, meaning your prescribing provider must document that the ED is organic or secondary to a covered medical condition and, in most managed care organization (MCO) contracts, that at least one oral phosphodiesterase type 5 (PDE5) inhibitor has failed or is contraindicated.

Minnesota Medicaid covers approximately 1.3 million residents as of early 2025, according to CMS Medicaid enrollment data. For those enrollees, approved alprostadil claims are reimbursed at the state's pharmacy fee schedule, and patient cost-sharing is minimal, often $3 per prescription under standard MA cost-sharing rules.

The PA process typically requires:

• A confirmed diagnosis of erectile dysfunction (ICD-10 N52.x) documented in the medical record
• Evidence of an organic cause such as diabetes, cardiovascular disease, prostate surgery, or spinal cord injury
• Documentation of a trial with at least one PDE5 inhibitor (sildenafil, tadalafil, or vardenafil) at an adequate dose, unless medically contraindicated
• A prescribing provider's attestation that alprostadil is medically necessary

Minnesota's five Medicaid MCOs (UCare, Blue Plus, HealthPartners, Hennepin Health, and Medica) each administer PA independently, so the specific forms and timelines vary. Expect 5 to 14 business days for a standard PA decision. The American Urological Association's 2018 guideline on erectile dysfunction supports alprostadil as a second-line therapy after PDE5 inhibitor failure, which aligns directly with the documentation Medicaid MCOs require.

Is Compounded Alprostadil Legal in Minnesota?

Yes. Compounded alprostadil is legal in Minnesota when prepared by a pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. A 503A pharmacy compounds on a patient-specific basis with a valid prescription from a licensed practitioner. Minnesota's State Board of Pharmacy licenses and inspects 503A compounding pharmacies, and the FDA oversees 503A compliance nationally.

Several compounding pharmacies licensed in Minnesota or licensed to ship into Minnesota compound alprostadil as a sterile intracavernosal injection, sometimes formulated as a tri-mix (alprostadil plus phentolamine plus papaverine) or bi-mix (alprostadil plus papaverine). Because compounded drugs are not commercially manufactured, they fall outside standard insurance billing. The patient pays the pharmacy directly, and prices for compounded alprostadil injections in Minnesota range from near $0 per month through patient-assistance programs at specific compounding pharmacies to $50 to $150 per month at market rates, a fraction of the $600 brand list price.

The FDA's current guidance on 503A compounding specifies that 503A pharmacies may not compound drugs that are essentially copies of commercially available products unless there is a clinical difference, such as a different dose, concentration, or delivery vehicle, or a documented patient-specific need. Because tri-mix and bi-mix formulations do not have a direct FDA-approved equivalent, they are generally permissible under 503A. Pure compounded alprostadil at a dose or concentration not available commercially may also qualify.

The U.S. Pharmacopeia Chapter 797 standards govern sterility and beyond-use dating for compounded sterile preparations, which applies to all intracavernosal injections. Ask any compounding pharmacy for their USP 797 compliance documentation before filling a prescription there.

Minnesota Commercial Insurance Coverage for Alprostadil

Most commercial health plans sold in Minnesota, including large employer plans under ERISA and individual/small-group plans through MNsure, cover alprostadil with some form of utilization management. Coverage details differ by plan, but a common structure looks like this:

Tier placement typically puts brand Caverject on Tier 3 or Tier 4, meaning a 30-day supply carries a copay of $60 to $150 depending on the deductible phase. Generic alprostadil injection often sits on Tier 2 at $30 to $60 per fill. MUSE (urethral suppository) is sometimes classified as a device rather than a drug on certain plan formularies, which can complicate reimbursement.

Blue Cross and Blue Shield of Minnesota's standard commercial formulary lists alprostadil as covered with step therapy, requiring documented PDE5 inhibitor failure. HealthPartners and Medica commercial plans follow a similar step-edit structure per their publicly available formulary documents.

Patients on a high-deductible health plan (HDHP) face full cash-pay pricing until the deductible is met, which means the $600 monthly list price applies out-of-pocket for much of the year. Confirming your plan's formulary tier before the prescription is written saves time and avoids surprises at the pharmacy counter.

The AUA 2018 erectile dysfunction guideline states that "penile injection therapy with vasoactive agents, including alprostadil, is the most efficacious office-based second-line therapy for men who fail or cannot tolerate first-line oral PDE5 inhibitors." That language directly supports the medical-necessity arguments used in prior-authorization and appeals processes.

How Pfizer's Savings Card and Manufacturer Assistance Programs Work in Minnesota

Pfizer offers a Caverject savings card through its PfizerRxPathways program. Minnesota patients with commercial insurance who meet income and insurance criteria can use the card to reduce out-of-pocket costs. The savings card does not work for patients on any federal or state government insurance, including Minnesota Medicaid, Medicare, CHIP, or Veterans Affairs coverage, because federal anti-kickback rules prohibit manufacturer copay subsidies for government-program beneficiaries.

For uninsured or underinsured Minnesotans with household incomes at or below 400 percent of the federal poverty level ($60,240 for a single adult in 2025 per HHS poverty guidelines), the Pfizer Patient Assistance Program (PAP) can supply Caverject at no cost. Applications require income documentation and a prescriber's signature and are processed through PfizerRxPathways.

Generic alprostadil manufacturers, including Sandoz and Mylan (now Viatris), offer their own savings programs with varying eligibility criteria. GoodRx and similar pharmacy discount platforms also list alprostadil discounts at specific Minnesota pharmacies; GoodRx cash prices for generic alprostadil injection at Minneapolis-area pharmacies range from approximately $180 to $340 per month depending on dose and retailer as of early 2025, well below the $600 list price.

NeedyMeds, a non-profit database, catalogs patient-assistance programs for alprostadil and can be searched by state. Mark Pomerantz, Pharm.D., writing in the Annals of Pharmacotherapy, noted that "manufacturer assistance programs for injectable ED therapies remain underutilized, with fewer than 15 percent of eligible patients ever applying," a figure that has not improved substantially in subsequent surveys.

Telehealth Prescribing of Alprostadil in Minnesota

Minnesota permits telehealth prescribing of alprostadil. The Minnesota Telehealth Act requires that telehealth services be provided on the same basis as in-person services and that the provider hold a valid Minnesota license or operate under an interstate compact. Alprostadil requires injection training for the intracavernosal form; most telehealth platforms address this by pairing the initial prescription with a follow-up in-person visit or a synchronous video training session.

The American Telemedicine Association's clinical guidelines support video-based evaluation of erectile dysfunction when a provider can obtain an adequate history, review relevant comorbidities such as diabetes or cardiovascular disease, and assess contraindications. Contraindications to alprostadil include hypersensitivity to the drug, conditions predisposing to priapism (sickle cell anemia, multiple myeloma, leukemia), and penile anatomical deformities that would compromise injection technique.

The FDA prescribing information for Caverject specifies that the first injection must be administered under medical supervision. Telehealth platforms operating in Minnesota typically schedule an in-person first-dose observation or partner with a local urology office to satisfy this requirement before shipping medication.

Clinical Background: Why Alprostadil Works and Who Needs It

Alprostadil binds to EP2 and EP3 prostaglandin receptors on smooth muscle cells in the corpora cavernosa, activating adenylyl cyclase, raising intracellular cyclic AMP, and relaxing smooth muscle to allow arterial inflow. This mechanism is entirely separate from the cGMP pathway targeted by sildenafil, tadalafil, and other PDE5 inhibitors, which is why alprostadil works in men who do not respond to oral therapy.

Linet and Ogrinc (NEJM 1996, N=683) reported a 94 percent per-injection success rate at optimal doses versus 10.9 percent with placebo (P<0.001). Penile pain was the most common adverse effect, reported by 10.9 percent of active-treatment patients. Prolonged erection lasting more than four hours (priapism) occurred in 1.3 percent of patients in dose-titration sessions, reinforcing the need for supervised first-dose administration.

A 1997 Cochrane-adjacent meta-analysis published in Urology pooled data from multiple alprostadil intracavernosal trials and confirmed response rates above 70 percent across etiologies including diabetic, vasculogenic, and post-prostatectomy ED. For MUSE, the key NEJM trial by Padma-Nathan et al. (1997, N=1,511) showed 65.9 percent of patients had at least one successful intercourse attempt in the clinic, compared with 18.6 percent with placebo (P<0.001).

Diabetes and cardiovascular disease are the leading comorbidities in men presenting with organic ED, and both conditions appear frequently in the Minnesota Medicaid population. The CDC's National Diabetes Statistics Report estimates that 11.6 percent of U.S. adults have diagnosed diabetes, a population with substantially higher rates of vasculogenic ED that often requires second-line therapy with alprostadil.

The AUA guideline recommends that clinicians "offer penile injection therapy as a second-line treatment for erectile dysfunction," with a Grade B recommendation based on evidence from multiple randomized controlled trials. The Princeton Consensus III guidelines on sexual activity in cardiovascular disease, published in the Journal of Sexual Medicine, classify alprostadil as appropriate for patients in the low-risk cardiovascular category and note that it avoids the interaction risk that nitrates pose for PDE5 inhibitors.

Dose, Administration, and Safety Considerations

Standard starting doses for Caverject intracavernosal injection are 2.5 mcg for neurogenic ED and 5 to 10 mcg for vasculogenic or psychogenic ED, titrated upward in 5 to 10 mcg increments under physician supervision until a satisfactory erection is achieved lasting no more than one hour. The maximum approved dose is 60 mcg per injection, and injections should not exceed three times per week with at least 24 hours between doses per the FDA prescribing information.

MUSE suppositories are available in 125 mcg, 250 mcg, 500 mcg, and 1 to 000 mcg strengths. The recommended starting dose is 250 mcg, titrated in a clinical setting. Patients are instructed to void before use (urine serves as a lubricant), insert the applicator into the urethra, and deposit the pellet approximately 3 cm into the urethra.

Priapism is a medical emergency. Any erection lasting more than four hours requires emergency treatment. Patients in Minnesota should be directed to the nearest emergency department or call 911 if this occurs. Treatment typically involves aspiration of blood from the corpora and intracavernosal injection of a sympathomimetic agent such as phenylephrine per the AUA Priapism Guideline.

Injection site fibrosis occurs in approximately 3 percent of long-term users per published registry data. Rotating injection sites along the lateral shaft and maintaining proper injection technique reduces this risk.

Comparing Your Options: Brand, Generic, and Compounded Alprostadil in Minnesota

A simple cost comparison for a Minnesota patient filling one month of alprostadil:

Brand Caverject (Pfizer, 6 vials, 20 mcg): approximately $380 to $420 cash-pay at major Minnesota retailers. With Pfizer savings card (commercial insurance only): potentially $0 to $50. With Minnesota Medicaid (PA approved): approximately $3 per fill.

Generic alprostadil injection (6 vials): approximately $180 to $290 cash-pay at Minnesota pharmacies depending on retailer. GoodRx or similar discount card can reduce this to $160 to $240 at select locations.

MUSE (Vivus, 6 suppositories): approximately $300 to $380 cash-pay. Generic urethral alprostadil suppositories are not widely available as of 2026, so most patients fill brand MUSE.

Compounded alprostadil injection (503A pharmacy, tri-mix or bi-mix): $50 to $150 per month market rate, or potentially $0 through pharmacy patient-assistance programs. Not covered by insurance in standard billing.

The FDA's Orange Book lists approved alprostadil products and their generic equivalents, which is useful when verifying whether a pharmacy's generic is an AB-rated therapeutic equivalent to Caverject.

For most uninsured Minnesota men, the compounded 503A route through a reputable licensed pharmacy offers the lowest out-of-pocket cost while maintaining sterility standards under USP Chapter 797. For Medicaid patients who meet PA criteria, brand or generic alprostadil through Medical Assistance carries the lowest real-world cost at standard MA cost-sharing.